COUR Pharmaceuticals
PrivateLast Round
Series B
Jun 18, 2026
Total Funding Raised
$155M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
COUR Pharmaceuticals is a clinical-stage biotechnology company that develops antigen-specific immune tolerance therapies to treat autoimmune and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
COUR Pharmaceuticals Comparables
Compare COUR Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Imcyse | 86% | |
| Anokion | 85% | |
| Topas Therapeutics | 84% |
COUR Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 18, 2026 | ||||
| Series A | Jan 30, 2024 | ||||
| VC Round | Sep 7, 2022 |
COUR Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Roche Venture Fund | Series A, Series B |
| Roche Venture Fund | Series A |
| Angelini Ventures | Series B, Series A |
| JDRF | Series A, Series B |
| Lumira Ventures | Series A, Series B |
| Pfizer | Series A |
| Chimera Capital Management | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 55% MoM.
- Jun 18, 2026
$50M round led by Lumira Ventures and Roche Venture Fund.
Recent news
Latest coverage and updates
- receives_financingJun 18, 2026
Cour Pharma received financing of $50M in Series B on Jun 18th '26.
COUR Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about COUR Pharmaceuticals's valuation, stock price, and market status.
Is Cour Pharma a public or private company?
Cour Pharma is a private company.
What is the current stock price of Cour Pharma?
Cour Pharma is a private company with no public stock price. No recent secondary market data is available.
How much is Cour Pharma worth (valuation)?
Valuation information for Cour Pharma is not publicly available.
Can I buy Cour Pharma stock?
Cour Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Cour Pharma's last funding round?
Cour Pharma's most recent funding round was Series B on June 18, 2026.
Who are the main investors in Cour Pharma?
Key investors in Cour Pharma include Roche Venture Fund, Angelini Ventures, Lumira Ventures, Alpha Wave Global.
Will Cour Pharma IPO soon?
No public IPO plans have been announced for Cour Pharma.
How can I track Cour Pharma secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Cour Pharma's secondary market activity and sign up for updates.